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Abstract
Introduction: In this study, we sought to determine the diagnostic value and clinical laboratory associations of
autoantibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in systemic
lupus erythematosus (SLE).
Methods: Autoantibodies against recombinant ribosomal P proteins (aRibPR0, aRibPR1 and aRibPR2) and antibodies
against native ribosomal P heterocomplex (aRibPNH) were determined in sera from patients with SLE (n = 163),
systemic sclerosis (n = 66), Sjögren’s syndrome (n = 54), rheumatoid arthritis (n = 90) and healthy donors (n = 100)
using enzyme-linked immunosorbent assay. Test results were correlated to medical records, including the American
College of Rheumatology criteria, the Systemic Lupus Erythematosus Disease Activity Index 2000, laboratory data
and medications of all SLE patients.
Results: Sensitivities of 22.0% for aRibPR0, 14.9% for aRibPR2, 14.3% for aRibPNH and 10.7% for aRibPR1 were
obtained at a specificity of 99%. The assay for aRibPR0 detection demonstrated the best performance in receiver-
operating characteristics analysis, with aRibPR0 detectable in 10% of anti-Smith antibody and anti-double-stranded
DNA-negative sera at a specificity of 100%. ARibPR0 positivity was associated with lymphocytopenia. ARibPR1
+
patients had significantly higher g-glutamyl transpeptidase (GGT) levels than their aRibPR1
- counterparts. No specific
damage occurred in aRibP
+ lupus patients compared with a group of age-, sex- and nephritis-matched aRibP
-
lupus patients within 3 years.
Conclusions: The determination of antibodies against ribosomal P proteins improves the diagnosis of SLE and
should therefore be implemented in upcoming criteria for the diagnosis or classification of SLE. High titers of
aRibPR0 can be associated with lymphocytopenia, and high titers of aRibPR1 can be associated with elevated GGT
levels. So far, there is no evidence for a prognostic value of aRibPs for damage.
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Systemic lupus erythematosus (SLE) is a chronic, multifa-
ceted rheumatic disease which is characterised by the gen-
eration of autoantibodies predominantly directed against
nuclear proteins and nucleic acids [1,2]. However, antibo-
dies against cytoplasmatic antigens such as those binding
to ribosomal P proteins (aRibPs) have been reported to be
specific for SLE as well [2,3]. In contrast to anti-Smith
(anti-Sm) and anti-double-stranded DNA (anti-dsDNA)
antibodies, anti-ribosomal P protein antibodies are not
included in the current American College of Rheumatol-
ogy (ACR) classification criteria for SLE [4,5].
The human ribosomal phosphoproteins P0 (38 kDa), P1
(19 kDa) and P2 (17 kDa) are located within the 60S ribo-
somal subunit, forming a pentameric complex consisting
of a P0 anchor and two P1/P2 heterodimers [3]. The subu-
nits of that pentamer have a common immunodominant
epitope at the carboxyl terminus [6], which can lead to
cross-reactions of anti-ribosomal P antibodies with P0, P1
and P2 units. P proteins can also exist as ribosome-free
P0, P1 and P2 forms in the cytoplasm [6,7]. Notably, the
P0-like protein is also detectable in the plasma membranes
of hepatocytes, lymphocytes and other cells [8-11].
The prevalence of anti-ribosomal antibodies depends
on the disease activity, the patient’s ethnicity and the
antigens used in detection systems [12-14]. There are
reports about clinical associations of anti-ribosomal pro-
tein antibodies with short disease duration [15], rash
[16,17], lymphocytopenia [18] and lupus hepatitis
[11,19-23]. Ohira et al. [22] showed that patients with
lupus hepatitis have significantly higher and more fre-
quent levels of antibodies against recombinant ribosomal
P0 protein (aRibPR0) than patients with autoimmune
hepatitis. There are also contradictory reports of patients
with juvenile onset SLE [24-27], neuropsychiatric SLE
[3,28,29], lupus nephritis class V [3,27,30], high disease
activity [15,16,26,31] and low levels of complement com-
ponent 3 (C3) or complement component 4 (C4)
[16,17,22,32].
A comparative investigation of the clinical laboratory
associations of antibodies against recombinant ribosomal
P0, P1 and P2 proteins (aRibPR0, aRibPR1a n da R i b P R2)
has never been conducted. Thus, the purpose of the pre-
sent work was to determine the diagnostic value of antibo-
dies against native ribosomal P heterocomplex (aRibPNH),
aRibPR0, aRibPR1a n da R i b P R2f o rS L Ea n dt oa n a l y s e
their associations with disease features and future damage.
Materials and methods
Study participants
Altogether 479 serum samples were obtained from the
following groups: (1) patients with SLE (n = 163), who
fulfilled the American College of Rheumatology (ACR)
1982 revised criteria for the classification of SLE [4], (2)
patients with systemic sclerosis (SSc, n =6 6 )w h om e t
the ACR 1980 criteria for scleroderma [33], (3) patients
with primary Sjögren’s syndrome (pSS, n = 54) who ful-
filled the preliminary European League Against Rheuma-
tism criteria of Vitali et al. [34], (4) patients with
rheumatoid arthritis (RA, n =9 0 )w h om e tt h eA C R
1987 revised criteria for the classification of rheumatoid
arthritis [35] and (5) healthy donors (HD, n = 100).
Disease activity of SLE patients was defined based on
the Systemic Lupus Erythematosus Disease Activity
Index 2000 (SLEDAI 2000) [36-38] in 101 patients: 6 of
them had no activity (SLEDAI score 0), 35 were mildly
active (0 < SLEDAI ≤ 5), 41 had moderate disease activ-
ity (5 < SLEDAI ≤ 10), 14 were highly active (10 < SLE-
DAI ≤ 20), and 5 had very high activity (SLEDAI > 20).
Juvenile onset was diagnosed when the age at diagnosis
was 18 years or younger according to the Pediatric
Rheumatology International Trials Organization [39].
Twenty-four (14.7%) patients with juvenile onset SLE
and 139 (85.3%) patients with adult onset SLE were stu-
died. Disease damage was measured according to the
criteria of the Systemic Lupus International Collabora-
tive Clinics (SLICC) [40,41] and the weighted damage
score (WDS) [40]. All patients were recruited from the
outpatient and inpatient facilities of the Department of
Rheumatology and Clinical Immunology, Charité Uni-
versity Hospital, Berlin, Germany. The Ethics Commit-
tee of the Medical Faculty of Charité University Hospital
approved the study, and written informed consent was
obtained from all subjects. Sera from healthy donors
were used in cooperation with University of Lübeck,
Germany. Written informed consent was obtained from
all healthy subjects.
Measurement of antibodies
Microtiter plates (Nunc, Roskilde, Denmark) were
coated with 1 μg/ml full-length recombinant ribosomal
protein P0, P1 or P2 expressed in insect cells (DIA-
RECT, Freiburg, Germany). Sera diluted 1:201 in phos-
phate-buffered saline (PBS) and 0.1% (wt/vol) casein
were added and allowed to react for 30 minutes, fol-
lowed by three washing cycles with PBS 0.05% (vol/vol)
and Tween 20. For detection of bound antibodies, the
plates were incubated with antihuman immunoglobulin
(IgG) peroxidase conjugate (EUROIMMUN, Lübeck,
Germany) for 30 minutes, washed three times and
allowed to react with tetramethylbenzidine (EUROIM-
MUN) for 15 minutes. After addition of acidic stopping
solution (EUROIMMUN), the optical density (OD) was
read at 450 nm using an automated spectrophotometer
(Spectra Mini; Tecan, Crailsheim, Germany). All steps
were performed at room temperature. A highly positive
index patient serum was used to generate a standard
curve consisting of three calibrators (2, 20 and 200
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Page 2 of 11relative units (RU)/ml). Relative units per milliliter were
calculated for all samples using this three-point standard
curve. The analytical reproducibility of all aRibP assays
was evaluated by repeated testing of two serum samples
(10 determinations each) in the same run, giving intraas-
say coefficients of variation (CV) of 2.4% (aRibPR0), 2.1%
(aRibPR1) and 2.7% (aRibPR2), respectively. Relationships
between sensitivity and specificity at different cutoff
values were examined for all assays by receiver-
operating characteristics (ROC) curve analyses, allowing
also for the determination of test characteristics at pre-
defined specificities.
The anti-RibPNH enzyme-linked immunosorbent assay
(ELISA) (IgG, CV 2.6%), anti-Sm ELISA, anti-dsDNA radio-
immunoassay (RIA) (Farr assay) and anti-dsDNA ELISA are
commercially available assays from EUROIMMIUN and
were performed following the manufacturer’si n s t r u c t i o n s .
Statistical analysis
Statistical analyses were performed using GraphPad Prism
5 software (GraphPad Software, La Jolla, CA, USA). The
diagnostic significance of antiribosomal proteins N, P0, P1
and P2 antibodies was assessed and areas under the curve
(AUCs) were created using ROC analysis. To determine
associations, the Mann-Whitney U test (for comparing
medians between groups; MWT), Fisher’s exact test (FET)
and Spearman’s rank test (SRT) were used. Two-tailed
t-tests were used throughout with an a set at 0.05.
Results
Reactivity and diagnostic significance of antiribosomal
proteins N, P0, P1 and P2 antibodies
Antibodies against ribosomal PNH, PR0, PR1 and PR2 pro-
teins (Figure 1), Sm and dsDNA (ELISA and Farr assays)
were measured in sera from 163 SLE patients, 210 disease
controls and 100 healthy donors to define and compare
the sensitivity and specificity in ROC curve analysis (Table
1). For aRibPNH, a sensitivity of 5.5% and a specificity of
100% were calculated using the manufacturer’s cutoff (20
RU/ml). At a predefined specificity of 98% among 210
patients with other rheumatic diseases (SSc, pSS and RA),
only five (2.4%), four (1.9%), four (1.9%) and four (1.9%)
h a de l e v a t e da R i b P NH, aRibPR0, aRibPR1a n da R i b P R2
titers, respectively. At the same specificity among 100
healthy donors, only zero (0%), one (1.0%), two (2.0%) and
two (2.0%) patients had high titers of aRibPNH, aRibPR0,
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Figure 1 Graphs showing levels of antiribosomal P protein antibodies in SLE, other rheumatic diseases and healthy donors.
Autoantibodies directed against (a) native ribosomal P heterocomplex (aRibPNH), (b) recombinant ribosomal P0 protein (aRibPR0), (c)
recombinant ribosomal P1 (aRibPR1) and (d) recombinant ribosomal P2 protein (aRibPR2) were measured using enzyme-linked immunosorbent
assay. Dotted lines represent the distinct cut-offs based on ROC curve analysis at specificities of 95% (dotted line), 98% (broken line) and 99%
(dotted and broken line). Values >30 RU/ml were set to 30 RU/ml for clearer arrangement of the figures. SLE, systemic lupus erythematosus; SSc,
systemic sclerosis; pSS, primary Sjögren’s syndrome; RA, rheumatoid arthritis; HD, healthy donors. RU, relative units.
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Page 3 of 11aRibPR1a n da R i b P R2. Among antiribosomal P protein
antibodies, aRibPR0 had the highest performance with
regard to criteria such as AUC and maximum sum of sen-
sitivity and specificity, followed by aRibPNH (Table 1). All
test criteria of aRibPR0 were inferior to those of the anti-
dsDNA ELISA or the Farr assay, but were almost equal to
those of the anti-Sm ELISA.
Patients negative for aRibPNH but positive for aRibPRP0-2
Although the native heterocomplex of ribosomal P con-
tains all immunological domains of the subunits P0, P1
and P2, there were considerable differences in the cut-
offs and in sensitivities for the detection of aRibPNH,
aRibPR0, aRibPR1 and aRibPR2 (Table 1), with outstand-
ing results for aRibPR0.
Thus, we further investigated whether there were
patients negative for aRibPNHb u tp o s i t i v ef o ra R i b P R0,
aRibPR1o ra R i b P R2 (Figure 2). Sera fulfilling these cri-
teria would point out that there are some epitopes of
ribosomal P proteins that are not accessible to autoanti-
bodies because of the spatial conformation of the native
heterocomplex.
Table 1 Test values of antiribosomal PNH, PR0, PR1 and PR2 antibodies calculated in receiver-operating characteristics
analysis
a
Statistics aRibPNH aRibPR0 aRibPR1 aRibPR2 Anti-Sm Anti-dsDNA Farr
assay
Anti-dsDNA
ELISA
Area under curve 0.7014 0.7368
b 0.5811 0.6220 0.6791 0.8463 0.8621
95% CI 0.65 to
0.75
0.69 to 0.79 0.52 to
0.64
0.57 to 0.67 0.62 to
0.74
0.80 to 0.89 0.82 to 0.90
P value <0.0001 <0.0001 0.0021 <0.0001 <0.0001 <0.0001 <0.0001
Sensitivity at 95% specificity cutoff 24.4% (4.5) 29.2% (2.7)
b 20.4% (6.6) 20.2% (10.5) 38.7% (2.0) 61.4% (5.4) 53.9% (73.9)
Sensitivity at 98% specificity cutoff 19.1% (6.7) 22.0% (3.7)
b 16.1% (8.4) 17.9% (12.1) 33.7% (2.4) 56.4% (6.5) 42.9% (105.8)
Sensitivity at 99% specificity cutoff 14.3% (9.4) 22.0% (4.2)
b 10.7%
(13.0)
14.9% (13.9) 19.6% (4.8) 55.8% (6.8) 37.4% (151.0)
Sensitivity at 100% specificity cutoff 11.9 (11.5)
b
11.3% (9.1) 8.9% (14.7) 11.3% (17.4) 12.3% (7.9) 49.1% (9.0) 31.3% (169.0)
Maximum sum of specificity and
sensivity
133.2% 140.7%
b 118.2% 117.9% 138.9% 161.8% 160.8%
aaRibPNH, antibody against native ribosomal P heterocomplex; aRibPR0, antibody against recombinant ribosomal P0 protein; aRibPR1, antibody against
recombinant ribosomal P1 protein; aRibPR2, antibody against recombinant ribosomal P2 protein; anti-Sm, anti-Smith antibody; anti-dsDNA, anti-double-stranded
DNA antibody; ELISA, enzyme-linked immunosorbent assay; 95% CI, 95% confidence interval;
bhighest values of sensitivity, area under the curve and lowest
cutoff values (in parentheses) among autoantibodies against ribosomal P protein (aRibP).
A) B)
Figure 2 Frequencies of aRibPR0, aRibPR1 and aRibPR2 in aRibPNH-negative lupus patients. (a) Results according to specificity of 99% are
shown in a Venn diagram. (b) Corresponding to Figure 2a, those sera were selected that were exclusively positive for aRibPR0, aRibPR1o r
aRibPR2 among aRibPNH-negative SLE patients. To further show exact and comparable signal intensities, fold change indices in relation to the
given cutoffs of each recombinant aRibP protein (see also Table 1) were calculated. ARibPNH, antibodies against native ribosomal P
heterocomplex; aRibPR0, antibodies against recombinant ribosomal P0 protein; aRibPR1, antibodies against recombinant ribosomal P1 protein;
aRibPR2, antibodies against recombinant ribosomal P2 protein; aRibPs, anti-ribosomal P protein antibodies.
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- patients there
were 19 (13.5%) positive for aRibPR0, six (4.3%) positive
for aRibPR1 and 11 (7.8%) positive for aRibPR2. Some of
those sera were further exclusively positive for one of
the recombinant aRibPs and showed an increased titer
up to twofold of the corresponding cutoff (Figure 2b).
Diagnostic value of anti-ribosomal P protein antibodies
in SLE
To investigate the auxiliary diagnostic value of antiribo-
somal P protein antibodies in SLE, we searched for
patients who were negative for antibodies against
dsDNA and Sm, but positive for aRibPNH, aRibPR0,
aRibPR1o ra R i b P R2 at a specificity of 100% (Figure 3).
This analysis was performed twice, taking either the
results of the anti-dsDNA ELISA (Figure 3a) or those of
the Farr assay (Figure 3b).
Among 163 SLE patients, there were 11 (6.7%) indivi-
duals who could be diagnosed only by detection of
aRibPs, while 63 (38.7%) patients were regularly diag-
nosed by the presence of anti-dsDNA or anti-Sm anti-
bodies. Considering the excellent Farr assay, these
Positive in Anti-dsDNA ELISA
OR Anti-Sm-ELISA ?
n=63
SLE-DIAGNOSIS
n=100
Positive for any 
Anti-RibP ELISA ?
n=11, thereof
• n=7   RibNH+
• n=10 RibRP0+
• n=7   RibRP1+
• n=9   RibRP2+
n=89
163 SLE patients
Positive in Farr assay 
OR Anti-Sm-ELISA ?
n=89
SLE-DIAGNOSIS
n=74
Positive for any 
Anti-RibP ELISA ?
n=5, thereof
• n=2  RibNH+
• n=4  RibRP0+
• n=2  RibRP1+
• n=2  RibRP2+
n=69
163 SLE patients A) B)
yes no
yes no
yes no
yes no
Figure 3 Additional diagnostic benefit of antiribosomal P protein antibodies in lupus patients. Both flow charts aim to demonstrate the
additional diagnostic value of antiribosomal P protein antibodies (anti-RibP) in the absence of anti-double-stranded DNA (anti-dsDNA) and anti-
Smith (anti-Sm) antibodies for lupus diagnostics. The cutoffs of all test systems were set to ensure an absolute specificity of 100% (see Table 1
for cutoffs). Anti-dsDNA and anti-Sm antibodies were selected because they are highly specific for systemic lupus erythematosus (SLE) (instead
of, for example, anti-phospholipid antibodies) and are part of American College of Rheumatology classification criteria for SLE [4]. Flowcharts
differ only in the test system used for the detection of anti-dsDNA antibodies. (A) Anti-dsDNA enzyme-linked immunosorbent assay (ELISA) and
(B) Farr assay. RibPNH
+, native ribosomal P heterocomplex-positive; RibPR0
+, recombinant ribosomal P0 protein-positive; RibPR1
+, recombinant
ribosomal P1 protein-positive; RibPR2
+, recombinant ribosomal P2 protein-positive.
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Page 5 of 11relations adjusted to 89 (54.6%) individuals with regular
diagnosis and five (3.1%) individuals with additional
diagnosis only by the presence of aRibP.
Comparison of disease features in aRibP
+ vs. aRibP
- SLE
patients
To determine the special characteristics of lupus
patients with elevated aRibPs, we compared medical
records, including ACR criteria, SLEDAI 2000 items and
laboratory parameters, including autoantibodies, immu-
nosuppressants and antimalarials, with those of aRibP
-
lupus patients. All clinical laboratory results and detailed
demographic information about the study cohort are
shown in Table 2.
ARibPNH
+ patients fulfilled significantly more ACR
criteria and more often had photosensitivity. Moreover,
the frequency of patients with decreased C3 levels was
higher among aRibPNH
+ patients. Lymphocytopenia was
associated with the presence of aRibPR0, and a higher
g-glutamyl transpeptidase (GGT) level was found in
aRibPR1
+ patients. Anti-Sm, anti-dsDNA and anti-U1-
ribonucleoprotein (anti-U1-RNP) antibodies were much
more frequent in all aRibP
+ patients.
Comparison of disease damage in aRibP
+ vs. aRibP
- SLE
patients
To study the prognostic role of ribosomal P protein
antibodies, SLICC scores and WDS were assessed in
aRibP
+ patients and in an age-, sex- and nephritis-
matched group of aRibP
- patients at the time of blood
sampling and 3 years later. Changes in damage scores
(ΔSLICC, ΔWDS) were calculated, and both groups
were separately compared. Damage scores from 41 of all
58 aRibP
+ patients were completely assessable at the
time of blood sampling and 3 years later. There were 22
aRibPNH
+,2 7a R i b P R0
+,1 8a R i b P R1
+ and 23 aRibPR2
+
patients. SLICC and WDS correlated significantly with
disease duration and the ageso fp a t i e n t s ,b u tn o tw i t h
ACR scores or with anti-dsDNA, anti-Sm or any antiri-
bosomal P protein antibodies. Total disease damage and
damage to every organ system separately was not signifi-
cantly higher in aRibP
+ patients than in their aRibP
-
counterparts within these 3 years. Thus, we found no
prognostic role for aRibP.
Discussion
In this study, the diagnostic potential, clinical laboratory
associations and correlations with disease damage of
antibodies directed against the native ribosomal hetero-
complex and its recombinantly produced constituents
P0, P1 and P2 were investigated. ARibPR0 revealed the
best diagnostic performance among all aRibP types and
offered the most diagnostic benefit among sera negative
for anti-dsDNA and anti-Sm antibodies. Furthermore,
aRibPR0
+ lupus patients had significantly lower lympho-
cyte counts than their aRibPR0
- counterparts. Finally, no
prognostic relevance was found for any of the aRibPs
during a 3-year period.
Our results concerning the prevalence and high speci-
ficity of aRibPs for SLE agree with data described before
[3,42]. We further found sensitivities of PR0>P NH>
PR2>P R1 at specificities of 98% to 99% and PNH>P R0
=P R2>P R1 at a specificity of 100% in a cohort of 163
lupus patients. This is in contrast to another study
where sensitivities of PR2=P R1=P R0 were determined
at a specificity of 100% in a cohort of 50 SLE patients
[13]. Different detection systems and patient cohorts
might have contributed to these divergent observations.
Since all three subunits of aRibPs share the carboxyl-
terminal epitope, it is of interest to note that an ELISA
(referred as anti-C22 ELISA) detecting antibodies
against this shared epitope reached the same sensitivity
of 22% at a specificity of nearly 99% as aRib PR0i no u r
Berlin patient cohort [43].
We have additionally demonstrated that negativity of
aRibPNH does not automatically imply negativity of anti-
bodies against its subunits, especially those against ribo-
somal P0. This could be due to immunologically
relevant epitopes that are freely accessible using RibPR0
alone, but not within the spatial conformation of the
native heterocomplex. A biological reason for the higher
frequency of aRibPR0 might be the disposability of ribo-
somal P0-like protein in the cell membranes of many
cells, which could contribute to an increased immuno-
genicity [8-11].
Among the vast quantity of antibodies that are detect-
able in SLE, antibodies against dsDNA and Sm are
highly specific and therefore most useful for the verifica-
tion of the diagnosis. However, aRibPs are also discussed
as a diagnostic criterion. Therefore, we asked whether
aRibPs provide additional diagnostic benefit in direct
comparison to anti-dsDNA and anti-Sm antibodies.
Exactly 10% of sera negative in the anti-Sm and anti-
dsDNA ELISAs were positive for aRibPR0 at a specificity
of 100%. Even the comparison including the Farr assay
revealed that 5.4% of all anti-Sm ELISA and anti-
dsDNA RIA (Farr assay) negative sera were positive for
aRibPR0 at 100% specificity. Thus, laboratories using less
sensitive assays seem to benefit more from testing for
aRibP in suspected cases of SLE. However, to be sure,
all patients with suspected diagnosis of SLE should be
tested for aRibP. Finally, we conclude that the determi-
nation of antibodies against ribosomal P proteins, espe-
cially those against P0, would improve the classification
and diagnosis of SLE.
By comparing disease features of lupus patients with
elevated aRibPs to their seronegative counterparts, we
could not confirm an association of aRibP positivity
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Page 6 of 11Table 2 Comparison of the frequency: demographical and clinical data in aRibP-positive and negative SLE patients
a
aRibPNH aRibPR0 aRibPR1 aRibPR2
Clinical data All patients
(n = 163)
Positive
(n = 30)
Negative
(n = 133)
P value Positive
(n =3 4 )
Negative
(n = 129)
P value Positive
(n = 24)
Negative
(n = 139)
P value Positive
(n = 28)
Negative
(n = 135)
P value
Demographics
Age in years,
b median 37.0 36.5 37.0 0.317 35.0 37.0 0.081 35.0 37.0 0.326 37.0 37.0 0.467
Age at onset,
c <18 years, % 19.7 15.6 13.9 1.000 24.3 16.8 0.338 22.2 17.7 0.592 26.7 16.7 0.203
Females,
c % 89.8 84.4 91.2 0.324 89.2 90 1.000 96.3 88.7 0.314 90 89.9 1.000
SLE duration in months,
b median 108.0 97.0 109.0 0.716 69.0 109.0 0.118 62.0 109.0 0.147 96.0 107.0 0.756
ACR criteria n = 163 n =3 0 n = 133 n =3 4 n = 129 n =2 4 n = 139 n =2 8 n = 135
Number of ACR criteria,
b median 6.00 7.00
d 6.00
d 0.031
d 7.00 6.00 0.059 6.50 6.00 0.236 7.00 6.00 0.076
Malar rash,
c % 66.2 73.3 64.6 0.402 70.6 65.1 0.684 70.8 65.5 0.815 71.4 65.2 0.662
Discoid rash,
c % 12.3 16.7 11.3 0.536 14.7 11.6 0.571 16.7 11.5 0.501 25.0 9.63 0.0504
Photosensitivity,
c % 46.6 63.3
d 42.9
d 0.046
d 58.8 43.4 0.125 62.5 43.9 0.121 53.6 45.2 0.533
Oral ulcers,
c % 18.4 23.3 17.3 0.441 23.5 17.1 0.456 12.5 19.4 0.573 17.9 18.5 1.000
Arthritis,
c % 84.1 90.0 82.7 0.417 94.1 81.4 0.111 91.7 82.7 0.373 96.4 81.5 0,0506
Serositis,
c % 44.2 36.7 45.9 0.419 38.2 45.7 0.561 41.7 44.6 0.828 39.3 45.2 0.677
Renal disorder,
c % 42.9 46.7 42.2 0.686 44.1 42.6 1.000 37.5 43.9 0.658 39.3 43.7 0.834
Epilepsy or psychosis,
c % 12.9 20.0 11.3 0.228 14.7 12.4 0.774 25.0 10.8 0.091 21.4 11.1 0.209
Hematologic,
c % 63.8 70.0 62.4 0.530 67.6 62.8 0.690 58.3 64.7 0.646 67.9 62.9 0.672
Immune disorder and ANA, % 100 100 100 - 100 100 - 100 100 - 100 100 -
SLEDAI n = 101 n =1 7 n =8 4 n =2 2 n =7 9 n =1 7 n =8 4 n =1 7 n =8 4
SLEDAI,
b median 6.00 6.00 6.00 0.517 6.00 6.00 0.886 6.00 6.00 0.915 6.00 6.00 0.256
Vasculitis,
c % 7.92 5.89 8.33 1.000 4.55 8.86 0.682 11.8 7.14 0.621 5.89 8.33 1.000
Arthritis,
c % 33.7 23.5 35.7 0.408 22.7 36.7 0.309 11.8
d 38.1
d 0.048
d 11.8
d 38.1
d 0.048
d
Hematuria,
c % 6.93 11.8 5.95 0.335 4.55 7.59 1.000 0.00 9.52 0.346 0.00 9.41 0.346
Proteinuria,
c % 9.90 17.6 8.33 0.366 9.09 10.1 1.000 5.88 10.7 1.000 5.88 10.7 1.000
Exanthema,
c % 32.7 11.8 36.9 0.0503 27.3 34.2 0.615 23.5 34.5 0.572 23.5 34.5 0.572
Alopecia,
c % 16.8 23.5 15.5 0.478 27.3 13.9 0.195 17.6 16.7 1.000 17.6 16.7 1.000
Pericarditis,
c % 6.93 5.88 7.14 1.000 9.09 6.33 0.645 11.8 5.95 0.335 5.88 7.14 1.000
Complement deficiency,
c % 57.4 64.7 55.9 0.597 68.2 51.2 0.331 58.8 57.1 1.000 64.7 55.9 0.597
Fever,
c % 3.96 0.00 4.67 1.000 4.55 3.79 1.000 0.00 4.76 1.000 0.00 4.76 1.000
Drugs
Prednisolone,
c % 89.9 93.1 89.2 0.738 90.9 89.7 1.000 86.9 90.4 0.706 88.9 90.3 0.734
Azathioprine,
c % 30.8 27.6 31.5 0.825 36.4 29.4 0.526 17.4 33.1 0.151 29.6 31.1 1.000
Cyclophosphamide,
c % 8.81 6.89 9.23 1.000 12.1 7.94 0.491 18.8 7.75 0.155 11.1 8.33 0.708
Mycophenolate mofetil,
c % 20.5 20.7 19.7 1.000 15.2 22.2 0.474 30.4 19.1 0.265 22.2 20.5 0.799
Methotrexate,
c % 3.04 3.23 3.01 1.000 8.33 1.56 0.071 7.69 2.17 0.179 3.45 2.96 1.000
Hydroxychloroquine sulfate,
c % 35.4 50.0 32.3 0.085 36.4 35.2 1.000 30.4 36.3 0.645 37.0 35.1 0.829
Laboratory
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1Table 2 Comparison of the frequency: demographical and clinical data in aRibP-positive and negative SLE patients
a (Continued)
Leukocytes,
b median 6.50 7.03 6.40 0.539 7.00 6.30 0.136 6.58 6.40 0.479 6.50 6.49 0.933
Lymphocytes,
b median 0.87 0.67 0.87 0.164 0.63
d 0.92
d 0.036
d 0.91 0.86 0.957 0.70 0.93 0.076
Monocytes,
b median 0.35 0.34 0.35 0.769 0.33 0.35 0.584 0.48 0.35 0.301 0.31 0.35 0.540
ALT,
b,e median 19.4 14.4 20.0 0.501 22.0 19.2 0.824 20.7 19.0 0.661 14.7 20.0 0.547
AST,
b,e median 25.0 28.0 24.9 0.212 25.5 25.0 0.953 27.5 24.9 0.129 25.0 25.0 0.568
GGT,
b,e median 23.0 26.0 21.6 0.278 24.0 21.1 0.423 29.0
d 21.0
d 0.047
d 29.0 21.1 0.108
Low C3,
c % 47.6 65.5
d 43.2
d 0.038
d 58.1 44.8 0.227 54.2 46.3 0.511 61.5 44.6 0.134
Low C4,
c % 34.7 37.9 33.9 0.670 38.7 33.6 0.672 37.5 34.1 0.816 38.4 33.9 0.656
CRP,
b median 0.38 0.30 0.40 0.771 0.28 0.42 0.454 0.25 0.42 0.379 26.0 25.9 0.803
ESR,
b median 24.0 25.0 24.0 0.616 22.0 25.0 0.740 21.5 25.0 0.572 23.0 24.5 0.819
Autoantibodies
High anti-Sm,
c % 33.7 63.3
d 27.1
d 4×1 0
-3d 70.6
d 24.2
d <10
-4d 66.7
d 28.1
d 7×1 0
-3d 60.7
d 28.1
d 0.002
d
Increased anti- dsDNA in ELISA,
c % 42.3 70.0
d 36.8
d 0.002
d 67.8
d 36.4
d 0.002
d 75.0
d 37.4
d 7×1 0
-3d 60.7
d 39.3
d 0.058
d
Increased anti- dsDNA in RIA,
c % 56.4 76.7
d 51.9
d 0.015
d 79.4
d 50.4
d 0.003
d 83.3
d 51.8
d 0.004
d 78.6
d 51.9
d 0.012
d
Increased anti- U1-RNP in anamnesis,
c % 28.9 59.1
d 21.7
d 0.001
d 50.0
d 23.3
d 0.021
d 62.5
d 23.5
d 0.003
d 54.5
d 22.7
d 0.007
d
Increased anti- nucleosomes,
c % 50.9 60.0 48.9 0.315 64.7 47.3 0.084 62.5 48.9 0.271 70.4
d 47.1
d 0.035
d
Increased anti- Ro/SS-A,
c % 40.5 50.0 38.3 0.304 41.2 40.3 1.000 37.5 41.0 0.824 39.3 40.7 1.000
Increased anti- La/SS-B,
c % 12.3 20.0 10.5 0.213 8.82 13.2 0.769 0.00
d 14.4
d 0.046
d 3.57 14.1 0.203
aSLE, systemic lupus erythematosus; ACR, American College of Rheumatology; ANA, antinuclear antibody; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; GGT, g-glutamyl transpeptidase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ELISA, enzyme-linked immunosorbent assay; RIA, radioimmunoassay; anti-Sm, anti-Smith antibody; anti-
dsDNA, anti-double-stranded DNA antibody; Ro/SS-A, anti- Sjögren’s syndrome antigen A; La/SS-B, anti- Sjögren’s syndrome antigen B; U1-RNP, U1-ribonucleoprotein; aRibP, anti-ribosomal P protein antibody;
aRibPNH, antibodies against native ribosomal P heterocomplex; aRibPR0, antibodies against recombinant ribosomal P0 protein; aRibPR1, antibodies against recombinant ribosomal P1 protein; aRibPR2, antibodies
against recombinant ribosomal P2 protein. All used autoantibody cutoffs were read out of receiver-operating characteristics analysis at a specificity of 98% (see Table 1);
bP values were calculated using the Mann-
Whitney U test;
cP values were calculated using Fisher’s exact test;
dstatistically significant findings, highlighted in bold;
eGGT values of men and from other laboratories have been standardized on cutoffs of GGT for
women at the Charité University Hospital.
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1with lupus nephritis, short disease duration, high disease
activity or juvenile onset. These results might be influ-
enced by the Caucasian ethnicity of the study cohort
and differences of the test systems. Cases of neuropsy-
chiatric lupus [28,29] and subtypes of lupus nephritis
were not recorded in our study.
The most striking association of aRibPs with disease
features was that aRibPR0
+ lupus patients had signifi-
cantly lower lymphocytes than aRibPR0
- lupus patients.
Interestingly, a P0-like protein is also detectable in the
plasma membranes of different cells, including lym-
phocytes [11]. Further, the aRibPs are able to bind and
penetrate T-cell lines [44,45], and especially aRibPR0
can induce apoptosis in Jurkat T-cells [46]. In that
context, our data confirm the thesis of Sun et al. [46]
that aRibPR0 contributes in a clinically relevant man-
ner to lymphocytopenia in SLE. Thus, clinicians should
keep aRibPR0 in mind as one differential diagnosis for
lymphocytopenia in SLE, along with viral status, drug
side effects, hematologic malignancies and other
factors.
Another remarkable, significant clinical laboratory
association was that aRibPR1
+ patients had an elevated
GGT value. The participation of aRibPs in liver pathol-
ogy of SLE was previously reported in cell cultures
[9,11,46] and in case reports [19-21]. However,
aRibPR0 were most frequently in focus because of their
membrane-bound isoform [8-11]. As such, in a study
of 61 Japanese patients [22], no significant association
was found between aRibPR0 and liver enzymes alanine
aminotransferase or aspartate aminotransferase, but
the GGT level was not assessed. The correlation
shown here between GGT and aRibPR1 indicates a
possible association of aRibP with lupus hepatitis.
However, we do not have a clear definition of lupus
hepatitis, and it is hard to rule out other causes, such
as nutrition, drugs and other autoimmune hepatitis
forms. Longitudinal analysis of aRibPs with liver func-
tion tests, including GGT in parallel, might reveal this
association best.
Up to now, accepted prognostic factors in SLE have
only been lupus nephritis and neuropsychiatric SLE.
No prognostic laboratory parameter is known. In this
study, we investigated whether aRibP
+ lupus patients
would develop more or specific disease damage mea-
sured by SLICC or WDS after 3 years than their
aRibP
- c o u n t e r p a r t s .H o w e v e r ,n os i g n i f i c a n tc o r r e l a -
tions with any of the antiribosomal P protein antibo-
dies could be found over a 3-year period. Conclusively,
we first show that aRibPs are not a prognostic para-
meter for damage in SLE. Further study with more
patients and over longer observation time frames could
strengthen this result.
Conclusions
In summary, antiribosomal P protein antibodies are very
specific for SLE, can also be found in patients with
negative anti-dsDNA and anti-Sm antibodies and there-
fore have to be discussed in the upcoming classification
and diagnostic criteria for SLE. Among all four investi-
gated aRibPs, aRibPR0 was the most abundant and
should be used for the diagnosis of SLE. High aRibPR0
titers can be associated with lymphocytopenia, and high
aRibPR1 titers can be associated with an elevated GGT
level. A prognostic role of antiribosomal P protein anti-
bodies is unlikely.
Abbreviations
aRibPNH: antibodies against native ribosomal P heterocomplex; aRibPR0:
antibodies against recombinant ribosomal P0 protein; aRibPR1: antibodies
against recombinant ribosomal P1 protein; aRibPR2: antibodies against
recombinant ribosomal P2 protein; aRibPs: anti-ribosomal P protein
antibodies.
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